BioPharmSignal logoBioPharmSignal

Biotech News

Immuneering to Present at the ESMO Congress 2026

Immuneering (IMRX)ImmuneeringClinical readout

- Trial in progress poster will highlight the ongoing Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer patients - NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer

Related news

IMRXImmuneering2026-10-02 13:00 EST

Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

IMRXImmuneering2026-09-10 11:30 EST

Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival

AUTLAutolus Therapeutics plc2026-10-05 12:30 EST

Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026

ERASErasca2026-09-10 12:00 EST

Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

REGNRegeneron Pharmaceuticals2026-10-06 11:00 EST

Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

RVMDRevolution Medicines2026-10-05 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

LYELLyell Immunopharma2026-09-10 20:05 EST

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

CGEMCullinan Therapeutics, Inc.2026-09-10 17:00 EST

Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

IDYAIDEAYA Biosciences2026-09-09 10:00 EST

IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma

View all latest news

Immuneering

Deep Cyclic Inhibitors Immuneering is a late-stage clinical oncology company developing Deep Cyclic Inhibitors for RAS-, RAF- and other MAPK-driven cancers. The approach is designed to produce durable pathway inhibition while limiting resistance, cachexia and treatment-related toxicity. Atebimetinib Atebimetinib is an oral, once-daily...

Recent company news

IMRXImmuneering2026-10-02 13:00 EST

Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

IMRXImmuneering2026-09-28 11:30 EST

Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer

IMRXImmuneering2026-09-24 11:30 EST

Immuneering to Present at the ESMO Congress 2026

IMRXImmuneering2026-09-10 11:30 EST

Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival

IMRXImmuneering2026-09-03 20:05 EST

Immuneering to Participate in Upcoming Investor Conferences

Stock data

Close
3.83 USD
Market cap
276.9M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States